BMK vs. APH, BXP, AGY, ANCR, OXB, NIOX, MXCT, AMS, BVXP, and TSTL
Should you be buying Benchmark stock or one of its competitors? The main competitors of Benchmark include Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Oxford Biomedica (OXB), NIOX Group (NIOX), MaxCyte (MXCT), Advanced Medical Solutions Group (AMS), Bioventix (BVXP), and Tristel (TSTL). These companies are all part of the "medical" sector.
Benchmark (LON:BMK) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Benchmark received 33 more outperform votes than Alliance Pharma when rated by MarketBeat users. Likewise, 72.62% of users gave Benchmark an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
In the previous week, Alliance Pharma had 3 more articles in the media than Benchmark. MarketBeat recorded 3 mentions for Alliance Pharma and 0 mentions for Benchmark. Alliance Pharma's average media sentiment score of 0.25 beat Benchmark's score of 0.00 indicating that Alliance Pharma is being referred to more favorably in the news media.
Alliance Pharma has a consensus price target of GBX 80.75, suggesting a potential upside of 131.04%. Given Alliance Pharma's higher possible upside, analysts clearly believe Alliance Pharma is more favorable than Benchmark.
Alliance Pharma has a net margin of -4.15% compared to Benchmark's net margin of -18.96%. Alliance Pharma's return on equity of -2.46% beat Benchmark's return on equity.
Alliance Pharma has higher revenue and earnings than Benchmark. Alliance Pharma is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.
91.8% of Benchmark shares are held by institutional investors. Comparatively, 66.7% of Alliance Pharma shares are held by institutional investors. 5.8% of Benchmark shares are held by company insiders. Comparatively, 11.8% of Alliance Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Benchmark has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Summary
Alliance Pharma beats Benchmark on 11 of the 17 factors compared between the two stocks.
Get Benchmark News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benchmark Competitors List
Related Companies and Tools
